Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of IMU-838 for Induction and Maintenance Therapy in Moderate-to-severe Ulcerative Colitis

Next Previous
X
Search
Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of IMU-838 for Induction and Maintenance Therapy in Moderate-to-severe Ulcerative Colitis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vidofludimus calcium (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms CALDOSE-1
  • Sponsors Immunic

    • Most Recent Events

    • 30 Aug 2024 This trial has been completed in Portugal (Global end date: 16 Nov 2022).
    • 17 Oct 2023 Results of Efficacy and Safety of Vidofludimus Calcium (Imu-838) in Patients with Moderately to Severely Active Ulcerative Colitis , presented at the 31st United European Gastroenterology Week
    • 16 Oct 2023 According to an Immunic media release, the company announced the presentation of data from this study in an oral prresentation at the United European Gastroenterology Week (UEGW) 2023, taking place October 14-17 in Copenhagen.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top